Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines, has granted 55,450 restricted stock units (RSUs) to four new employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (NASDAQ:SLDB) has received FDA Fast Track designation for SGT-501, its novel gene therapy treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT). This designation adds to previously received FDA IND clearance, Orphan Drug, and Rare Pediatric Disease designations.

SGT-501 is designed as a first-in-class AAV-based gene therapy that delivers a functional CASQ2 gene to cardiac muscle cells, targeting the underlying causes of CPVT, a life-threatening cardiac condition. The therapy has received both FDA IND clearance and Health Canada CTA approval.

The company plans to initiate a Phase 1b clinical trial in Q4 2025, which will be a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and efficacy of SGT-501.

Solid Biosciences (NASDAQ:SLDB) has received both FDA IND and Health Canada CTA approvals for SGT-501, their first-in-class cardiac gene therapy designed to treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The therapy has secured Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.

CPVT is a rare, life-threatening genetic heart condition with no currently approved therapies. The company plans to initiate a Phase 1b clinical trial in Q4 2025 to evaluate SGT-501's safety, tolerability, and efficacy. The therapy targets the underlying disease mechanism by addressing abnormal calcium releases from the sarcoplasmic reticulum in the heart.

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of inducement awards to new employees. The company issued 105,330 restricted stock units (RSUs) to seven newly hired employees.

The RSUs will vest over a four-year period, with equal installments vesting annually on the grant date anniversary. The awards were granted under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has granted 34,550 restricted stock units (RSUs) to two new employees. The RSUs will vest over four years, with 25% vesting annually on each grant date anniversary. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment. Vesting is contingent upon continued employment with Solid Biosciences through each vesting date.

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat on June 4, 2025, at 2:00 pm ET. The presentation will be accessible via live webcast on the company's website's Investor Events page, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.

Solid Biosciences (NASDAQ: SLDB) reported Q1 2025 financial results and provided updates on its gene therapy pipeline. The company's cash position strengthened to $306.9 million, extending runway into H1 2027. Net loss widened to $39.3 million from $24.3 million year-over-year.

Key pipeline updates include: 1) Ongoing participant dosing in the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, with positive initial data showing robust microdystrophin expression and improved biomarkers; 2) FDA-cleared IND for SGT-212 for Friedreich's Ataxia, with first participant dosing expected in H2 2025; 3) Planned IND submission for SGT-501 for CPVT in H1 2025.

The company's proprietary capsid AAV-SLB101 has secured 19 partnership agreements, with more expected. R&D expenses increased to $30.9 million, primarily due to increased costs for SGT-003 development.

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 81,000 restricted stock units (RSUs) to seven newly hired employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were granted under the Company's 2024 Inducement Stock Incentive Plan and are contingent upon continued employment through each vesting date. These grants were made as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.

The company's President and CEO, Bo Cumbo, will engage in a fireside chat scheduled for Wednesday, May 7, at 12:30 pm ET. Interested parties can access the presentation through a live webcast available on the Events page of the company's Investors section website.

Key Details:

• Event: The Citizens Life Sciences Conference
• Format: Fireside Chat
• Date & Time: May 7, 12:30 pm ET
• Replay Availability: 30-day archive access

Institutional investors seeking management meetings during the conference are advised to contact their Citizens representative.